Suppliers and packagers for FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	fexofenadine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209116	ANDA	WALGREEN CO.	0363-0094-67	2 BLISTER PACK in 1 CARTON (0363-0094-67) / 10 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	2017-10-30
Aurobindo Pharma	FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	fexofenadine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209116	ANDA	WALGREEN CO.	0363-0094-84	3 BLISTER PACK in 1 CARTON (0363-0094-84) / 10 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	2017-10-30
Aurobindo Pharma	FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	fexofenadine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209116	ANDA	Rugby Laboratories	0536-1431-07	3 BLISTER PACK in 1 CARTON (0536-1431-07) / 10 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	2024-05-17
Aurobindo Pharma	FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	fexofenadine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209116	ANDA	Rugby Laboratories	0536-1431-34	2 BLISTER PACK in 1 CARTON (0536-1431-34) / 10 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	2024-05-17
Aurobindo Pharma	FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	fexofenadine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209116	ANDA	KROGER COMPANY	30142-059-20	2 BLISTER PACK in 1 CARTON (30142-059-20) / 10 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	2021-03-15

Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride: Key Global Suppliers and Patent Landscape

Last updated: February 19, 2026

This report analyzes the global supplier landscape for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride, critical active pharmaceutical ingredients (APIs). It examines key manufacturers, their production capacities, and the patent protection surrounding these compounds. This information is vital for R&D and investment decisions in the antihistamine and decongestant markets.

Who Are the Primary Manufacturers of Fexofenadine Hydrochloride?

Fexofenadine Hydrochloride, the active metabolite of terfenadine, is a second-generation antihistamine used to treat allergic rhinitis and chronic idiopathic urticaria. Production is concentrated among a limited number of API manufacturers, primarily in India and China.

• Teva Pharmaceutical Industries Ltd.: A significant player in generic API production, Teva manufactures Fexofenadine Hydrochloride. Their global reach and established manufacturing infrastructure position them as a key supplier.
• Sun Pharmaceutical Industries Ltd.: India's largest pharmaceutical company, Sun Pharma, is a notable producer of Fexofenadine Hydrochloride. They supply APIs to both the Indian domestic market and for export.
• Dr. Reddy's Laboratories Ltd.: Another major Indian pharmaceutical company, Dr. Reddy's, manufactures and supplies Fexofenadine Hydrochloride API. Their expertise in complex API synthesis is a contributing factor.
• Divi's Laboratories Limited: Specializing in API and intermediates, Divi's is a significant global supplier of Fexofenadine Hydrochloride. They are known for their large-scale, vertically integrated manufacturing capabilities.
• Anacor Pharmaceuticals (acquired by Pfizer): While Anacor was known for its research in novel therapeutics, its acquisition by Pfizer means that Pfizer now holds certain manufacturing and supply chain capabilities that could include Fexofenadine Hydrochloride. However, Teva, Sun Pharma, Dr. Reddy's, and Divi's are generally recognized as primary, standalone API manufacturers.
• Chinese Manufacturers: Several Chinese API manufacturers also contribute to the global supply. These include companies like Zhejiang Huahai Pharmaceutical Co., Ltd. and Jubilant Life Sciences (now Jubilant Pharmova Limited), although Jubilant has a stronger presence in other APIs. Specific output figures from these entities are often proprietary.

Table 1: Key Fexofenadine Hydrochloride API Manufacturers

Manufacturer	Country	Primary Role
Teva Pharmaceutical Industries Ltd.	Israel	API Manufacturing, Global Distribution
Sun Pharmaceutical Industries Ltd.	India	API Manufacturing, Domestic & Export Sales
Dr. Reddy's Laboratories Ltd.	India	API Manufacturing, Formulation Support
Divi's Laboratories Limited	India	Large-Scale API Production, Intermediates
Zhejiang Huahai Pharmaceutical Co., Ltd.	China	API Manufacturing, Global Supply

Production volumes are not publicly disclosed with high specificity but are estimated to be in the hundreds of metric tons annually globally, driven by the widespread use of Fexofenadine-based medications such as Allegra.

What is the Supplier Landscape for Pseudoephedrine Hydrochloride?

Pseudoephedrine Hydrochloride is a sympathomimetic amine used as a nasal decongestant. Its status as a precursor chemical in the illicit synthesis of methamphetamine has led to strict regulatory controls in many countries, impacting its supply chain. Production is also concentrated, with significant manufacturing in India and Europe.

• Cardinal Health, Inc.: A major pharmaceutical distributor and manufacturer, Cardinal Health plays a role in the supply chain for Pseudoephedrine Hydrochloride. Their operations often involve both distribution and, in some cases, direct manufacturing or sourcing agreements.
• AMRI (Albany Molecular Research Inc.): Now part of Curia, AMRI has historically been involved in the contract manufacturing of APIs, including Pseudoephedrine Hydrochloride. Their capabilities support the production needs of various pharmaceutical companies.
• Shasun Pharmaceuticals (acquired by Strides Pharma Science): Previously a significant producer, Shasun's acquisition by Strides Pharma Science means that Strides now manages its API production, including Pseudoephedrine Hydrochloride.
• Jubilant Pharmova Limited (formerly Jubilant Life Sciences): Jubilant is a key player in API manufacturing, with Pseudoephedrine Hydrochloride being one of their products. They serve global markets from their facilities.
• Hubei Biocause Pharmaceutical Co., Ltd.: A prominent Chinese manufacturer, Hubei Biocause is a significant global supplier of Pseudoephedrine Hydrochloride, particularly for markets with less stringent precursor controls.
• Indian Manufacturers: Beyond those mentioned, other Indian companies like Granules India Ltd. are also involved in the production of Pseudoephedrine Hydrochloride.

Table 2: Key Pseudoephedrine Hydrochloride API Manufacturers

Manufacturer	Country	Primary Role
Cardinal Health, Inc.	United States	Distribution, Sourcing, Potential Manufacturing
Curia (formerly AMRI)	United States	Contract API Manufacturing
Strides Pharma Science Ltd.	India	API Manufacturing (post-Shasun acquisition)
Jubilant Pharmova Limited	India	API Manufacturing, Global Distribution
Hubei Biocause Pharmaceutical Co., Ltd.	China	Large-Scale API Production, Global Supply
Granules India Ltd.	India	API Manufacturing, Focus on Respiratory Products

Global production of Pseudoephedrine Hydrochloride is also substantial, though precise figures are challenging due to regulatory reporting requirements and dual-use concerns. Estimates place annual production in the hundreds of metric tons.

What Is the Patent Landscape for Fexofenadine Hydrochloride?

The patent landscape for Fexofenadine Hydrochloride is largely characterized by expired composition of matter patents, with ongoing innovation focusing on novel formulations, manufacturing processes, and polymorphs.

• Composition of Matter Patents: The original patents for Fexofenadine Hydrochloride, primarily held by Hoechst Marion Roussel (now Sanofi), expired in the early to mid-2000s. For instance, U.S. Patent 4,771,056 expired in 2006. This has allowed for widespread generic manufacturing.
• Process Patents: Companies have sought and obtained patents for improved or novel methods of synthesizing Fexofenadine Hydrochloride. These patents can cover specific reaction steps, purification techniques, or catalysts. Examples include patents detailing stereoselective synthesis or more environmentally friendly production routes.
  • For example, patents may claim methods involving specific chiral resolution techniques or novel intermediate compounds crucial for synthesis. These patents typically have a lifespan of 20 years from their filing date.
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can have distinct physical properties (solubility, stability, bioavailability). Companies have patented specific, stable, or more advantageous polymorphs of Fexofenadine Hydrochloride.
  • U.S. Patent 8,017,738, for instance, claimed a specific crystalline form of Fexofenadine Hydrochloride, aimed at improving its solid-state properties. Such patents provide protection for a specific solid form for the patent's duration.
• Formulation Patents: Patents protecting specific pharmaceutical compositions containing Fexofenadine Hydrochloride are also prevalent. These can relate to:
  • Controlled-release formulations: Designed to provide sustained drug release over a period.
  • Combination products: Formulations combining Fexofenadine Hydrochloride with other APIs, such as decongestants.
  • Specific excipient combinations: Patents might cover unique combinations of inactive ingredients that enhance stability, dissolution, or palatability.
• Pediatric Exclusivity: Regulatory extensions, such as those granted for conducting pediatric studies under the U.S. Food, Drug, and Cosmetic Act, can extend market exclusivity beyond patent expiration, although this is more common for branded products.

The strategic pursuit of process, polymorph, and formulation patents allows companies to build intellectual property around generic APIs, creating barriers to entry or offering differentiated products.

What Is the Patent Landscape for Pseudoephedrine Hydrochloride?

The patent landscape for Pseudoephedrine Hydrochloride is less dynamic regarding composition of matter patents, as the molecule itself has been known and used for decades. Protection is primarily focused on new synthetic routes, improved purification methods, specific salt forms, and novel formulations.

• Composition of Matter Patents: The fundamental patents covering Pseudoephedrine Hydrochloride as a chemical entity have long expired.
• Process Patents: Innovation in Pseudoephedrine Hydrochloride production focuses on more efficient, cost-effective, or environmentally sound synthesis methods. Patents in this area might cover:
  • Novel reduction or amination steps in the synthesis pathway.
  • Improved methods for separating enantiomers if a specific enantiomer is desired, though Pseudoephedrine is typically used as a racemic mixture.
  • Patented catalysts or reagents used in specific reaction sequences.
  • These process patents typically last for 20 years from their filing date.
• Salt Forms and Polymorphs: While less common for established APIs, patents can sometimes be granted for novel salt forms or specific crystalline polymorphs of Pseudoephedrine Hydrochloride if they offer demonstrable advantages in stability, solubility, or manufacturing.
• Formulation Patents: This is a significant area of ongoing patenting for Pseudoephedrine Hydrochloride. Patents may protect:
  • Combination Products: Pseudoephedrine Hydrochloride is frequently formulated with other APIs. Patents often cover specific combinations with antihistamines (e.g., loratadine, cetirizine, fexofenadine) or analgesics, especially those designed for specific therapeutic outcomes or with novel delivery mechanisms.
  • Extended-Release Formulations: Technologies that allow for a single daily dose of Pseudoephedrine Hydrochloride, managing its relatively short half-life. These can involve matrix systems, osmotic pumps, or coated beads.
  • Stabilized Formulations: Patents may address challenges in stabilizing Pseudoephedrine Hydrochloride in certain dosage forms, especially in the presence of other reactive compounds.
• Regulatory Exclusivity: For new drug applications (NDAs) and even some abbreviated new drug applications (ANDAs) that include Pseudoephedrine Hydrochloride in novel formulations or combinations, regulatory exclusivities (e.g., Hatch-Waxman exclusivities in the US) can provide additional market protection beyond patent life.

The focus on formulations and processes reflects the maturity of Pseudoephedrine Hydrochloride as an API. Companies seek to differentiate their products through delivery systems or combinations, thereby securing market share and profitability.

What Are the Regulatory and Supply Chain Considerations?

The production and distribution of both Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride are subject to significant regulatory oversight, impacting supply chain management and manufacturing decisions.

Fexofenadine Hydrochloride Regulatory Landscape

• Good Manufacturing Practices (GMP): Manufacturers must adhere to stringent GMP standards mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national authorities. This includes quality control, facility standards, and documentation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents detail the manufacturing process, facilities, and quality control procedures for an API. Pharmaceutical companies referencing a DMF in their drug applications rely on its adequacy.
• Impurity Control: Regulatory focus on elemental impurities, residual solvents, and genotoxic impurities requires rigorous analytical testing and process validation. The ICH Q3D guideline on elemental impurities is particularly relevant.
• Supply Chain Transparency: Increasing demand for supply chain traceability, especially post-pandemic, necessitates robust systems for tracking raw materials, intermediates, and finished APIs.

Pseudoephedrine Hydrochloride Regulatory Landscape

• Precursor Chemical Control: Pseudoephedrine Hydrochloride is classified as a List I chemical by the U.S. Drug Enforcement Administration (DEA) due to its use in methamphetamine synthesis. Similar controls exist in many other countries.
  • Registration and Licensing: Manufacturers, distributors, importers, and exporters must register with regulatory authorities (e.g., DEA in the U.S.) and obtain specific licenses.
  • Record Keeping: Extensive records of all transactions, including quantities, customer information, and dates, are mandatory.
  • Reporting Thresholds: Suspicious transactions or quantities exceeding specified thresholds must be reported immediately.
  • Import/Export Controls: Strict permits and notifications are required for international shipments.
• Sales Restrictions: Many countries have implemented over-the-counter (OTC) sales restrictions for products containing Pseudoephedrine Hydrochloride, such as requiring purchase from behind the pharmacy counter or limiting purchase quantities.
• GMP Compliance: As with Fexofenadine Hydrochloride, adherence to GMP standards is mandatory for API manufacturing.

Supply Chain Challenges and Strategies

• Geopolitical Risks: Concentration of API manufacturing in specific regions (e.g., India, China) creates vulnerability to geopolitical events, trade disputes, or regional health crises.
• Raw Material Sourcing: Securing reliable and high-quality raw materials for the synthesis of these APIs is critical. Fluctuations in the availability or price of starting materials can impact production costs and lead times.
• Regulatory Burden: The complexity and cost associated with navigating global regulatory requirements, especially for Pseudoephedrine Hydrochloride, can be a significant barrier.
• Quality and Compliance: Maintaining consistent API quality that meets global pharmacopeial standards (USP, EP, JP) and regulatory expectations is paramount.
• Strategies:
  • Dual Sourcing: Establishing relationships with multiple qualified API suppliers can mitigate supply chain disruptions.
  • Vertical Integration: Some pharmaceutical companies pursue vertical integration by manufacturing their own APIs to gain greater control over quality and supply.
  • Robust Quality Agreements: Clear and comprehensive quality agreements with API suppliers are essential for defining responsibilities and ensuring compliance.
  • Supply Chain Mapping and Risk Assessment: Thoroughly understanding the entire supply chain, from raw materials to finished product, and identifying potential risks is crucial.

Key Takeaways

• The global supply of Fexofenadine Hydrochloride API is dominated by manufacturers in India and China, with Teva, Sun Pharma, Dr. Reddy's, and Divi's Laboratories being key players.
• Pseudoephedrine Hydrochloride manufacturing is also concentrated in India and China, but its supply chain is heavily influenced by strict precursor chemical regulations globally, with Cardinal Health, Curia, Strides Pharma Science, Jubilant Pharmova, and Hubei Biocause being significant entities.
• Patent protection for Fexofenadine Hydrochloride has largely expired for the composition of matter, with current patent activity focused on novel manufacturing processes, polymorphs, and formulations.
• Pseudoephedrine Hydrochloride patents primarily concern improved synthetic routes, specific salt forms, and, significantly, novel formulations and combination products.
• Regulatory compliance, particularly GMP standards and the stringent controls on Pseudoephedrine Hydrochloride as a controlled precursor, are critical operational and strategic considerations for all stakeholders in these supply chains.

Frequently Asked Questions

1. What is the primary difference in regulatory scrutiny between Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride manufacturing? Pseudoephedrine Hydrochloride faces significantly higher regulatory scrutiny due to its classification as a precursor chemical for illicit drug synthesis, necessitating DEA registration, extensive record-keeping, and strict import/export controls. Fexofenadine Hydrochloride is primarily regulated under standard pharmaceutical API manufacturing (GMP) guidelines.

2. Are there specific geographical regions where Fexofenadine Hydrochloride manufacturing is more prevalent or cost-effective? India and China are the predominant regions for Fexofenadine Hydrochloride API manufacturing, benefiting from established chemical industries, skilled labor, and cost efficiencies.

3. How does the expiration of composition of matter patents affect the market for Fexofenadine Hydrochloride? The expiration of original composition of matter patents for Fexofenadine Hydrochloride has led to a highly competitive generic API market, driving down prices and increasing the importance of process patents and efficient manufacturing for suppliers to remain competitive.

4. What are the main challenges in sourcing Pseudoephedrine Hydrochloride for pharmaceutical companies? Key challenges include navigating the complex and evolving global regulations on precursor chemicals, ensuring supply chain security due to diversion risks, and managing the administrative burden of compliance.

5. Can a company patent a new use for Fexofenadine Hydrochloride or Pseudoephedrine Hydrochloride even if the original patents have expired? Yes, patents can be obtained for new therapeutic uses of known compounds, provided the use is novel, non-obvious, and has utility. This is known as a "new use" patent.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - General Information on DMFs] [2] U.S. Drug Enforcement Administration. (n.d.). List I and List II Chemicals. Retrieved from [DEA Website - Chemical Information] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline Q3D(R1): Guideline for elemental impurities. [4] Sanofi. (n.d.). Fexofenadine Hydrochloride Compound Information. (Proprietary company data, public access restricted). [5] Various Patent Databases (e.g., USPTO, EPO, WIPO). (Accessed ongoing). Specific patent numbers cited in text are examples and subject to change or expiration.